首页|SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic

SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
  • 维普
The record speed at which Chinese scientists identified severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)and shared its genomic sequence with the world,has greatly facilitated the development of coronavirus disease(COVID-19)diagnostics,drugs,and vaccines.It is unprecedented in pandemic control history to develop a dozen successful vaccines in the first year and to immunize over half of the global population in the second year,due to the efforts of the scientific community,biopharmaceutical industry,and regulatory agencies worldwide.The challenges are both great and multidimensional due to the rapid emergence of virus variants and waning of vaccine immunity.Vaccination strategies need to adapt to these challenges to keep population immunity above the herd immunity threshold,by increasing vaccine coverage,especially for older adults and young people,and providing timely booster doses with homologous or heterologous vaccine boosts.Further research should be undertaken to develop more effective vaccines against SARS-CoV-2 variants and to understand the best prime-boost vaccine combinations and immunization strategies to provide sufficient and sustainable immune protection against COVID-19.

COVID-19pandemicsSARS-CoV-2vaccination

Yiming Shao、Yingqi Wu、Yi Feng、Wenxin Xu、Feng Xiong、Xinxin Zhang

展开 >

Chinese Center for Disease Control and Prevention,Beijing 102206,China

Changping Laboratory,Beijing 102206,China

Department of Infectious Diseases,Research Laboratory of Clinical Virology,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China

Department of Policy Science,Central Committee of the Chinese Peasants and Workers Democratic Party,Beijing 100011,China

展开 >

国家自然科学基金

U20A20362

2022

医学前沿
高等教育出版社

医学前沿

CSTPCDCSCDSCI
影响因子：1.362
ISSN：2095-0217
年,卷(期)：2022.16(2)
  • 52